van der Heijde D, et al. - In this Phase 3, 24-month, placebo-controlled trial, ORAL Scan (NCT00847613), 797 candidates were assessed to estimate the efficiency of tofacitinib 5 or 10 mg twice daily (BID) including structural progression, and safety in cases with active rheumatoid arthritis (RA) and also to analyze the methotrexate inadequate response (MTX-IR). They observed following maintained and similar constituents between tofacitinib doses: ACR20/50/70 responses, proportions of patients achieving DAS28-4(ESR)-defined remission or low disease activity, Clinical Disease Activity Index, Simplified Disease Activity Index, and Boolean remission, and Health Assessment Questionnaire Disability Index. They reported similar safety events, in type and frequency for both the tofacitinib doses.